Inventor
BRUGGEN PIERRE VAN DER
BE11 patents
Patents
11 patentsUS5571711ANov 5, 1996
Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
LUDWIG INST CANCER RES69 citations96
US5683886ANov 4, 1997
Tumor rejection antigens which correspond to amino acid sequences in tumor rejection antigen precursor bage, and uses thereof
LUDWIG INST CANCER RES51 citations95
US5558995ASep 24, 1996
Peptides which are derived from tumor rejection antigen precursor molecule MAGE-1, which complex to MHC molecule HLA-C clone 10, and uses thereof
LUDWIG INST CANCER RES17 citations81
US5629166AMay 13, 1997
Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-C-clone 10/MAGE-1 derived peptides, and methods for treating said individuals
LUDWIG INST CANCER RES13 citations73
US7371845B2May 13, 2008
MAGE-A3 peptides presented by HLA class II molecules
LUDWIG INST CANCER RES2 citations62
US6093540AJul 25, 2000
Method for diagnosing a disorder characterized by expression of a BAGE tumor rejection antigen precursor
LUDWIG INST CANCER RES1 citations62
US6638512B1Oct 28, 2003
Method for treating subjects by using BAGE tumor rejection antigen precursors or tumor rejection antigens
LUDWIG INST CANCER RES1 citations61
US6465184B1Oct 15, 2002
Isolated nucleic acid molecule encoding peptides which form complexes with MHC molecules HLA-Cw*1601 and uses thereof
LUDWIG INST CANCER RES2 citations61
US6110694AAug 29, 2000
Methods for determining complexes of tumor rejection antigens and HLA-Cw*160/molecules
LUDWIG INST CANCER RES2 citations61
US6328971B1Dec 11, 2001
MAGE-1 derived nona peptides, and compositions thereof
LUDWIG INST CANCER RES0 citations51
US6680056B1Jan 20, 2004
Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of hla-cw 1601/mage-1 derived peptides, and methods for treating said individuals
LUDWIG INST CANCER RES0 citations49